{"meshTags":["Animals","Drug Resistance, Neoplasm","Humans","Indoles","Melanoma","Proto-Oncogene Proteins B-raf","Sulfonamides"],"meshMinor":["Animals","Drug Resistance, Neoplasm","Humans","Indoles","Melanoma","Proto-Oncogene Proteins B-raf","Sulfonamides"],"genes":["BRAF kinase","BRAF(V600E) mutation"],"publicationTypes":["News"],"abstract":"In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation.","title":"Vemurafenib.","pubmedId":"22037033"}